438 research outputs found
Recombinant nanoparticles decorated with a near-infrared fluorescent protein for in vivo imaging
Meteorites as witnesses and products of the evolution of the solar system, threat and resource for the future
Π ΡΡΠΎΠΉ Π²Π²ΠΎΠ΄Π½ΠΎΠΉ Π»Π΅ΠΊΡΠΈΠΈ Π·Π°ΡΡΠ°Π³ΠΈΠ²Π°ΡΡΡΡ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½ΠΈΡ ΠΎ ΠΏΡΠΎΠΈΡΡ
ΠΎΠΆΠ΄Π΅Π½ΠΈΠΈ ΠΌΠ΅ΡΠ΅ΠΎΡΠΈΡΠΎΠ² ΠΊΠ°ΠΊ ΠΏΡΠΎΠΈΠ·Π²ΠΎΠ΄Π½ΡΡ
ΡΠ²ΠΎΠ»ΡΡΠΈΠΈ Π°ΡΡΠ΅ΡΠΎΠΈΠ΄ΠΎΠ² ΠΈ ΠΊΠΎΠΌΠ΅Ρ (ΠΎΡΠ½ΠΎΠ²Π½Π°Ρ ΡΠ΅ΠΌΠ°), Π° ΡΠ°ΠΊΠΆΠ΅ ΡΠ³ΡΠΎΠ·Π°, ΡΠ²ΡΠ·Π°Π½Π½Π°Ρ Ρ ΠΌΠ΅ΡΠ΅ΠΎΡΠΈΡΠ°ΠΌΠΈ, Π°ΡΡΠ΅ΡΠΎΠΈΠ΄Π°ΠΌΠΈ ΠΈ ΠΊΠΎΠΌΠ΅ΡΠ°ΠΌΠΈ, ΠΈ ΡΠ΅ΠΌΠ° ΠΌΠ΅ΡΠ΅ΠΎΡΠΈΡΠΎΠ², Π°ΡΡΠ΅ΡΠΎΠΈΠ΄ΠΎΠ² ΠΈ ΠΊΠΎΠΌΠ΅Ρ ΠΊΠ°ΠΊ ΠΊΠΎΡΠΌΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠ΅ΡΡΡΡΠΎΠ².The introductory lecture addresses understanding of the origin of meteorites as product of evolution of asteroids and comets (major topic); the threats associated with meteorites, asteroids and comets and meteorites, asteroids and comets as cosmic resources.Π Π°Π±ΠΎΡΠ° ΠΏΠΎΠ΄Π΄Π΅ΡΠΆΠ°Π½Π° Π³ΡΠ°Π½ΡΠΎΠΌ Π ΠΎΡΡΠΈΠΉΡΠΊΠΎΠ³ΠΎ Π½Π°ΡΡΠ½ΠΎΠ³ΠΎ ΡΠΎΠ½Π΄Π° 17-12-01441
Development of a technology for expression of recombinant human erythropoietin in cultured mammalian cells using alphavirus expression system
Currently there are no industrial eukaryotic expression systems other than transient
expression from plasmids or expression from genes integrated into host genome. Both approaches (use
of eukaryotic plasmids or chromosomal integration) suffer from poor scalability and often from poor
yields. Although, in laboratory settings, effective means for transducing of cultured cells to express
foreign proteins and for high-level transient expression were developed based on viral genomes. We
thought to develop a scalable and suitable for industrial application technology for the production of
recombinant human erythropoietin (EPO) in mammalian cell cultures using an expression vector based
on the genome of RNA virus
Development of a technology for expression of recombinant human erythropoietin in cultured mammalian cells using alphavirus expression system
Currently there are no industrial eukaryotic expression systems other than transient
expression from plasmids or expression from genes integrated into host genome. Both approaches (use
of eukaryotic plasmids or chromosomal integration) suffer from poor scalability and often from poor
yields. Although, in laboratory settings, effective means for transducing of cultured cells to express
foreign proteins and for high-level transient expression were developed based on viral genomes. We
thought to develop a scalable and suitable for industrial application technology for the production of
recombinant human erythropoietin (EPO) in mammalian cell cultures using an expression vector based
on the genome of RNA virus
Development of a recombinant foot -and-mouth disease vaccine
Foot-and-mouth disease (FMD) is important disease of cloven-foot animals including
cows and swine. Although annual vaccination against the FMD is mandated in regions of South
Kazakhstan, outbreaks of the disease are registered every year. These outbreaks result in huge economic
losses because international rules require culling of all the diseased and contacted animals and all
products from these animals must be destroyed. Currently available anti-FMD vaccines are all produced
using the original technology of inactivation of virus (foot-and-mouth disease virus, FMDV) grown in
cell cultures. Recombinant anti-FMD vaccine is a long anticipated development in the industry because
the recombinant vaccine is safe and compatible with diagnostic tests for discrimination of diseased and
vaccinated animals (DIVA)
Development of a recombinant foot -and-mouth disease vaccine
Foot-and-mouth disease (FMD) is important disease of cloven-foot animals including
cows and swine. Although annual vaccination against the FMD is mandated in regions of South
Kazakhstan, outbreaks of the disease are registered every year. These outbreaks result in huge economic
losses because international rules require culling of all the diseased and contacted animals and all
products from these animals must be destroyed. Currently available anti-FMD vaccines are all produced
using the original technology of inactivation of virus (foot-and-mouth disease virus, FMDV) grown in
cell cultures. Recombinant anti-FMD vaccine is a long anticipated development in the industry because
the recombinant vaccine is safe and compatible with diagnostic tests for discrimination of diseased and
vaccinated animals (DIVA)
Split core technology allows efficient production of virus-like particles presenting a receptor-contacting epitope of human IgE
Immunoglobulin E (IgE) plays a central role in type I hypersensitivity including allergy
and asthma. Novel treatment strategy envisages development of a therapeutic vaccine designed to elicit
autologous blocking antibodies against the IgE. We sought to develop an IgE-epitope antigen that induces
antibodies against a receptor-contacting epitope on human IgE molecule
- β¦